Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Sept.  12, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) is highlighting new data that demonstrate the potential benefits of treatment with TYSABRI® (natalizumab), PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a) in specific multiple sclerosis (MS) patient populations. Results obtained in real-world clinical practice are being presented at the 35th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) and 24th Annual Conference of Rehabilitation in MS in Stockholm (September 11-13).

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

CAMBRIDGE, Mass., Sept.  11, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis (MS). These findings are being presented at the 35th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) and 24th Annual Conference of Rehabilitation in MS in Stockholm (September 11-13).

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

Canon

Annaly Capital

Regeneron Pharmaceuticals

Biogen Inc. (BIIB), Regeneron Pharmaceuticals Inc. (REGN), Canon Inc. (CAJ) and Annaly Capital Management Inc. (NLY) have declined to their respective three-year lows.

Stocks That Fell to 3-Year Lows in the Week of Sept. 6

Alexion Pharma

Canadian Solar

DaVita

Rush Enterprises

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

5 Price-to-Book Value Picks for September

Gilead Sciences

Which stock wins in a battle between these two big biotechs?

Better Buy: Gilead Sciences vs. Biogen.

CBRE Group

Stryker

T. Rowe Price Group

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market

Celgene

Which stock wins in a match-up between these two biotechs?

Better Buy: Biogen (BIIB) vs. Celgene (CELG)

Tesla

Tesla (NASDAQ: TSLA) and Biogen (NASDAQ: BIIB) have similar market caps of roughly $40 billion and both companies have seen their stocks fall by roughly 25% this year. While Biogen stock has declined after it ended phase-3 trials of its Alzheimer’s drug Aducanumab in March, Tesla’s stock has been.

Which Stock: Tesla or Biogen? 2 Worlds. Same Price

Invitae

CAMBRIDGE, Mass. and SAN FRANCISCO, Aug.  20, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Invitae Corporation (NYSE: NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease. Clinical studies have demonstrated that early diagnosis and treatment of SMA may prevent the development of severe symptoms, improve motor function and slow the progression of the disease.

Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients

Northrop Grumman

PepsiCo

ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.

5 ROE Stocks to Profit as Trade War Spurs Volatility

The biotech had $4.3 billion in sales at risk.

Biogen Hedged Its Bet and Won Big

Biogen (BIIB) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Biogen (BIIB)

Lockheed Martin

Top 5 ROE Stocks to Buy as Dovish Fed Stance Spurs Volatility

Cutting expenses and repurchasing shares will only get the drugmaker so far.

Biogen Raises Guidance as It Looks to the Pipeline for Growth

Evercore

Diamondback Energy

Knight-Swift Transportation Holdings

Toll Brothers

Biogen and 4 Other Stocks Show Rapid Revenue Growth

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2019 Results - Earnings Call Transcript

Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
The post Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat appeared first on InvestorPlace.

Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat

Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower taxes.

Multiple sclerosis drug helps Biogen beat Wall St. profit expectations

Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.

Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View

When Biogen Inc. (NASDAQ: BIIB) released its second-quarter financial results before the markets opened on Tuesday, the biotech giant said that it had $9.15 in earnings per share (EPS) and $3.60 billion in revenue.

Why Biogen’s Q2 Was So Great

Biogen (BIIB) beats estimates for both earnings and sales in the second quarter. It lifts sales and earnings expectations for the year.

Biogen (BIIB) Q2 Earnings & Sales Beat Estimates

Biogen (NASDAQ: BIIB) reported second-quarter earnings of $9.15 per share, which beat the analyst consensus estimate of $7.53 by 21.51%.

Biogen Reports Q2 Earnings Beat, Raises Guidance

Biogen reported a 72.4% rise in second-quarter profit, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.

Biogen profit rises 72%

Biogen earnings came in at $9.15 a share in the second quarter vs. views for $7.53.

Biogen Earnings Crush Views, But Biotech Giant Little Changed

Shares of Biogen Inc. BIIB, +0.52% surged 5.0% in premarket trading Tuesday, after the biotechnology company reported second-quarter earnings and revenue that were well above expectations and lifted its full-year outlook.

News for Biogen Stock (BIIB)